Why Did Bristol Myers Squibb (BMS) Pay $4.1 Billion for Turning Point Therapeutics?

Turning Point Therapeutics ($TPTX) was recently acquired by BMS for a whopping $4.1 billion in cash. Turning Point’s most advanced molecule is repotrectinib, a potential best-in-class ROS1/TRK/ALK tyrosine kinase inhibitor in Ph. I/II studies for cancer. This article explores the science behind repotrectinib, one of our 2021 Molecules of the Month, what properties make it valuable, and how we know.

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!